Showing 17,281 - 17,300 results of 74,138 for search '(( 50 ((ns decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (mean decrease)) ))', query time: 1.71s Refine Results
  1. 17281

    Image5_Suppression of PTRF Alleviates Post-Infectious Irritable Bowel Syndrome via Downregulation of the TLR4 Pathway in Rats.TIF by Hui-hui Zhou (11532046)

    Published 2021
    “…</p><p>Methods: Lipopolysaccharide (LPS) (5 μg/ml) was used to induce inflammatory injury in human primary colonic epithelial cells (HCoEpiCs). …”
  2. 17282
  3. 17283
  4. 17284
  5. 17285
  6. 17286
  7. 17287
  8. 17288

    Data_Sheet_1_Dendritic Cells Are Critical for the Activation and Expansion of Vδ2+ T Cells After Allogeneic Hematopoietic Transplantation.PDF by Xiaoyu Wang (182979)

    Published 2018
    “…In addition, we found that the recovery of DC subsets was significantly decreased, and the concentration of myeloid DCs (mDCs) correlated significantly with Vδ2<sup>+</sup> T cell recovery in the setting of allogeneic HSCT. …”
  9. 17289
  10. 17290

    Data Sheet 14_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  11. 17291

    Data Sheet 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  12. 17292
  13. 17293

    Data Sheet 8_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  14. 17294
  15. 17295

    Data Sheet 15_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  16. 17296

    Data Sheet 13_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  17. 17297

    Data Sheet 2_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  18. 17298

    Data Sheet 10_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
  19. 17299
  20. 17300

    Data Sheet 6_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx by Didar Murad (12220805)

    Published 2025
    “…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”